Genetic alterations, such as mutations in APC, KRAS, NRAS, BRAF, and PI3K, alongside MSI and PTEN disruptions, highlight the complexity of CRC pathways and their impact on disease progression and therapy resistance. The gene discussed is BRAF; the disease is colorectal carcinoma.